CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. (January 2014)

• Record Type: Journal Article
• Authors: Gill, Saar; Porter, David L
• Is Part Of: Expert opinion on biological therapy. Volume 14:Number 1(2014:Jan.)
• Page Start: 37
• Page End: 49
• Publication Date: 2014-01
• Subjects: Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1517/14712598.2014.860442
• Languages: English
• ISSNs: 1471-2598

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> Malignancies of the B lymphocyte or its precursor include B-cell non-Hodgkin lymphoma as well as chronic and acute lymphoid leukemias. These are among the most common hematologic malignancies and many patients with B-cell malignancies are incurable. Although most patients initially respond to first-line treatment, relapse is frequent and is associated with a poor prognosis. T cells that are genetically engineered to express chimeric antigen receptors (CARs) recognizing the B-cell-associated molecule CD19 have emerged as a potentially potent and exciting therapeutic modality in recent years.</p> <p> <bold> <italic>Areas covered:</italic> </bold> This review explores the current peer-reviewed publications in the field and a discussion of expert opinion.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> Genetic engineering of T cells has become clinically feasible and appears to be safe. Here we provide an insight into the process of patient selection, engineered T-cell production, infusion procedure, expected toxicities and efficacy of this exciting approach as it is practiced in the treatment of B-cell malignancies. Anti-CD19-redirected T cells likely represent the vanguard of an exciting new approach to treating cancer.</p> </abstract>